PolyPid Ltd. announced the introduction of PD01B, a new product candidate using its Kynatrix technology for treating diabetic foot infections (DFIs) with localized, controlled-release doxycycline. This development extends PolyPid's pipeline from infection prevention to treatment, leveraging clinical success from its lead product D-PLEX₁₀₀, which is under FDA review with a PDUFA date of November 28, 2026. PD01B aims to address the serious complications of DFIs by delivering high local antibiotic concentrations directly to wounds, potentially improving outcomes where systemic antibiotics fall short. The company plans a pre-IND meeting and first-in-human study for PD01B in the second half of 2027, while also preparing for the commercial launch of D-PLEX₁₀₀ in early 2027 pending FDA approval.
PolyPid's new product candidate PD01B is the subject, with this snapshot providing context from Pluang's Health sector as of Oct 28, 2026 19:11 WIB: Among 150 priced Health-sector US stocks, 42 advanced while 97 declined. Moderna (MRNA) traded at USD 204.53 with a Pluang order activity heavily skewed to selling at 80%, contrasting with Immunovant (IMVT) which rose 1.80% to USD 29.40, and MiniMed Group (MMED) which fell 1.74% to USD 18.60. Typical hold times ranged from 19 days for IMVT and MMED to 58 days for MRNA.
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
The Legacy Lab by Team One released its 2026 Legacy Makers 100 list, identifying brands consumers trust to have their best interests at heart and remain relevant long-term. St. Jude Children's Research Hospital topped the list for the second year. Th...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
